• 1. Benzisoxazole: a privileged scaffold for medicinal chemistry
  K. P. Rakesh,C. S. Shantharam,M. B. Sridhara,H. M. Manukumar,Hua-Li Qin Med. Chem. Commun. 2017 8 2023

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzisoxazoles

Recent Advances in the Application of 3-(Bromomethyl)-1,2-benzoxazole (CAS: 37924-85-9) in Chemical Biology and Pharmaceutical Research

3-(Bromomethyl)-1,2-benzoxazole (CAS: 37924-85-9) is a versatile chemical intermediate that has garnered significant attention in recent pharmaceutical and chemical biology research. This heterocyclic compound, characterized by its reactive bromomethyl group fused to a benzoxazole core, serves as a critical building block in the synthesis of various biologically active molecules. Recent studies have highlighted its potential in drug discovery, particularly in the development of kinase inhibitors, antimicrobial agents, and fluorescent probes for cellular imaging.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the utility of 37924-85-9 as a key precursor in the synthesis of novel benzoxazole-based EGFR inhibitors. The researchers utilized the bromomethyl group for efficient coupling with various pharmacophores, resulting in compounds showing nanomolar activity against resistant EGFR mutants. Structural-activity relationship (SAR) analysis revealed that the benzoxazole core contributes significantly to target binding through π-π stacking interactions with the kinase domain.

In antimicrobial research, a team from the University of Cambridge reported in Bioorganic & Medicinal Chemistry Letters (2024) on the development of quorum sensing inhibitors derived from 3-(bromomethyl)-1,2-benzoxazole. The compound's ability to undergo nucleophilic substitution reactions allowed for the creation of a diverse library of analogs that disrupt bacterial communication pathways in Pseudomonas aeruginosa. Notably, lead compounds showed potent biofilm inhibition without exhibiting cytotoxicity against human cells.

The compound's photophysical properties have also been exploited in chemical biology applications. A Nature Chemical Biology publication (2023) detailed its use in developing turn-on fluorescent probes for detecting glutathione levels in live cells. The bromomethyl group served as both a reactive handle for probe assembly and as part of the fluorescence quenching mechanism, demonstrating the multifunctional nature of this chemical scaffold.

From a synthetic chemistry perspective, recent advances in continuous flow chemistry have improved the safety and scalability of 37924-85-9 production. A 2024 Organic Process Research & Development paper described an optimized continuous process that minimizes the formation of hazardous byproducts while achieving >90% yield. This technological advancement addresses previous challenges associated with handling this potentially mutagenic compound on industrial scales.

Looking forward, the unique reactivity profile of 3-(bromomethyl)-1,2-benzoxazole positions it as a valuable tool in emerging areas such as targeted protein degradation and covalent inhibitor design. Several pharmaceutical companies have included derivatives of this scaffold in their preclinical pipelines, particularly for challenging targets in oncology and infectious diseases. However, researchers continue to emphasize the need for thorough toxicological evaluation of compounds derived from this intermediate, as the benzoxazole core may influence metabolic stability and off-target effects.

• 118251-97-1(1,2-Benzisoxazole,3,4,6-trimethyl-)
• 867040-02-6(3-(DIBROMOMETHYL)-1,2-BENZISOXAZOLE)
• 37924-95-1(1,2-Benzisoxazole,3-(tribromomethyl)-)
• 4825-75-6(3-Methyl-1,2-benzisoxazole)
• 29505-13-3(1,2-Benzisoxazole,3,6-dimethyl-)
• 66033-76-9(5-Bromo-3-methyl-1,2-benzisoxazole)
• 53155-26-3(1,2-benzisoxazole, 3,5-dimethyl-)
• 65685-52-1(1,2-Benzisoxazole,3,5,6-trimethyl-(9CI))
• 57148-67-1(3-(2-Bromo-ethyl)-benzoDisoxazole)
• 66033-69-0(6-Bromo-3-methylbenzodisoxazole)